SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aphton (apht)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rocket who wrote (57)3/9/1998 5:59:00 PM
From: rocket  Read Replies (1) of 95
 
mason630---Another banner day for the stock. Up impressively on good volume. I think the biotech sector in general is getting some institutional interest and when Wall St. finally figures out that Aphton will get a much higher percentage of profits/sales than any other biotech that has alliances with large pharmaceuticals, the stock will become even more attractive. Many biotechs have high burn rates as they devlop promising compounds and need alliances to provide them with up- front money since they have no revenues. The price they pay is that they often settle for miniscule amounts of sales or profits (5% to 20%, at best). Aphton, however, has had a very low burn rate and have been able to fund themselves adequately well with equity offerings. Therefore, when it came time for them to negotiate over Gastrimmune, they were able to negotiate from a position of strength. The result? APHT will get over 50%. Ultimately this will be extremely nice for shareholders. Keep in touch. Karl
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News